The effect of benralizumab on inflammation in severe asthma: a real-life analysis
Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on a...
Gespeichert in:
| Veröffentlicht in: | Therapeutic advances in respiratory disease Jg. 18; S. 17534666241304685 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London, England
SAGE Publications
01.01.2024
SAGE PUBLICATIONS, INC SAGE Publishing |
| Schlagworte: | |
| ISSN: | 1753-4666, 1753-4658, 1753-4666 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background:
Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.
Objectives:
The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.
Design:
This is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients.
Methods:
We conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months.
Results:
Twenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment (p < 0.0001) as well as an improvement in asthma control (p < 0.0001), health-related quality of life (p = 0.017) and lung function pre-BD FEV1 (L) (p = 0.02) and percentage (p = 0.004) and post-BD FEV1 (L) (p = 0.01) and percentage (p = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 (p < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = −0.79, p = 0.04). Moreover, the improvement of FEF25%–75% from baseline to 6 (rho = −0.53, p = 0.03) and 12 (rho = −0.62, p = 0.01) months negatively correlated with the duration of asthma disease.
In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation.
Conclusion:
Our data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission.
Plain language summary
Analysis of the effect of a biological therapy on severe asthma
Background: Asthma is estimated to affect almost 5%-8% of the European adult population, and 5%–10% of these patients suffer from a severe asthma form. Severe asthma is characterised by chronic airway inflammation despite traditional inhaled treatment and patients may experience acute flare ups requiring courses of steroids and eventually hospitalization leading to a poor quality of life. New biological drugs have been introduced to treat severe asthma characterized by inflammation in the blood and in the lungs. Benralizumab is a well known biological option for severe asthmatic patients. Methods: We provide data on 22 patients followed up in our tertiary severe asthma centre in Tradate, Italy, affected by severe eosinophilic asthma treated with benralizumab for at least one year. Results: Our data confirmed a rapid effect of benralizumab on respiratory symptoms, exacerbations and quality of life. In addition, we documented a significant improvement in lung function along with a normalization of inflammation in the blood and in the lungs, assessed with a non-invasive tool: the induced sputum. Conclusions: Interestingly, our data highlight the importance of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Additional studies are needed to implement its role in the management of asthma also in terms of response to treatment towards a personalized approach. |
|---|---|
| AbstractList | Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation. Design: This is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients. Methods: We conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months. Results: Twenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment (p < 0.0001) as well as an improvement in asthma control (p < 0.0001), health-related quality of life (p = 0.017) and lung function pre-BD FEV1 (L) (p = 0.02) and percentage (p = 0.004) and post-BD FEV1 (L) (p = 0.01) and percentage (p = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 (p < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = −0.79, p = 0.04). Moreover, the improvement of FEF25%–75% from baseline to 6 (rho = −0.53, p = 0.03) and 12 (rho = −0.62, p = 0.01) months negatively correlated with the duration of asthma disease. In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation. Conclusion: Our data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission. Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.BACKGROUNDBenralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.OBJECTIVESThe aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.This is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients.DESIGNThis is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients.We conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months.METHODSWe conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months.Twenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment (p < 0.0001) as well as an improvement in asthma control (p < 0.0001), health-related quality of life (p = 0.017) and lung function pre-BD FEV1 (L) (p = 0.02) and percentage (p = 0.004) and post-BD FEV1 (L) (p = 0.01) and percentage (p = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 (p < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = -0.79, p = 0.04). Moreover, the improvement of FEF25%-75% from baseline to 6 (rho = -0.53, p = 0.03) and 12 (rho = -0.62, p = 0.01) months negatively correlated with the duration of asthma disease.In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation.RESULTSTwenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment (p < 0.0001) as well as an improvement in asthma control (p < 0.0001), health-related quality of life (p = 0.017) and lung function pre-BD FEV1 (L) (p = 0.02) and percentage (p = 0.004) and post-BD FEV1 (L) (p = 0.01) and percentage (p = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 (p < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = -0.79, p = 0.04). Moreover, the improvement of FEF25%-75% from baseline to 6 (rho = -0.53, p = 0.03) and 12 (rho = -0.62, p = 0.01) months negatively correlated with the duration of asthma disease.In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation.Our data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission.CONCLUSIONOur data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission. Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation. Design: This is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients. Methods: We conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months. Results: Twenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment (p < 0.0001) as well as an improvement in asthma control (p < 0.0001), health-related quality of life (p = 0.017) and lung function pre-BD FEV1 (L) (p = 0.02) and percentage (p = 0.004) and post-BD FEV1 (L) (p = 0.01) and percentage (p = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 (p < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = −0.79, p = 0.04). Moreover, the improvement of FEF25%–75% from baseline to 6 (rho = −0.53, p = 0.03) and 12 (rho = −0.62, p = 0.01) months negatively correlated with the duration of asthma disease. In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation. Conclusion: Our data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission. Plain language summary Analysis of the effect of a biological therapy on severe asthma Background: Asthma is estimated to affect almost 5%-8% of the European adult population, and 5%–10% of these patients suffer from a severe asthma form. Severe asthma is characterised by chronic airway inflammation despite traditional inhaled treatment and patients may experience acute flare ups requiring courses of steroids and eventually hospitalization leading to a poor quality of life. New biological drugs have been introduced to treat severe asthma characterized by inflammation in the blood and in the lungs. Benralizumab is a well known biological option for severe asthmatic patients. Methods: We provide data on 22 patients followed up in our tertiary severe asthma centre in Tradate, Italy, affected by severe eosinophilic asthma treated with benralizumab for at least one year. Results: Our data confirmed a rapid effect of benralizumab on respiratory symptoms, exacerbations and quality of life. In addition, we documented a significant improvement in lung function along with a normalization of inflammation in the blood and in the lungs, assessed with a non-invasive tool: the induced sputum. Conclusions: Interestingly, our data highlight the importance of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Additional studies are needed to implement its role in the management of asthma also in terms of response to treatment towards a personalized approach. Plain language summary Analysis of the effect of a biological therapy on severe asthma Background: Asthma is estimated to affect almost 5%-8% of the European adult population, and 5%–10% of these patients suffer from a severe asthma form. Severe asthma is characterised by chronic airway inflammation despite traditional inhaled treatment and patients may experience acute flare ups requiring courses of steroids and eventually hospitalization leading to a poor quality of life. New biological drugs have been introduced to treat severe asthma characterized by inflammation in the blood and in the lungs. Benralizumab is a well known biological option for severe asthmatic patients. Methods: We provide data on 22 patients followed up in our tertiary severe asthma centre in Tradate, Italy, affected by severe eosinophilic asthma treated with benralizumab for at least one year. Results: Our data confirmed a rapid effect of benralizumab on respiratory symptoms, exacerbations and quality of life. In addition, we documented a significant improvement in lung function along with a normalization of inflammation in the blood and in the lungs, assessed with a non-invasive tool: the induced sputum. Conclusions: Interestingly, our data highlight the importance of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Additional studies are needed to implement its role in the management of asthma also in terms of response to treatment towards a personalized approach. Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation. Design: This is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients. Methods: We conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months. Results: Twenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment ( p < 0.0001) as well as an improvement in asthma control ( p < 0.0001), health-related quality of life ( p = 0.017) and lung function pre-BD FEV1 (L) ( p = 0.02) and percentage ( p = 0.004) and post-BD FEV1 (L) ( p = 0.01) and percentage ( p = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 ( p < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = −0.79, p = 0.04). Moreover, the improvement of FEF 25%–75% from baseline to 6 (rho = −0.53, p = 0.03) and 12 (rho = −0.62, p = 0.01) months negatively correlated with the duration of asthma disease. In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation. Conclusion: Our data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission. Analysis of the effect of a biological therapy on severe asthma Background: Asthma is estimated to affect almost 5%-8% of the European adult population, and 5%–10% of these patients suffer from a severe asthma form. Severe asthma is characterised by chronic airway inflammation despite traditional inhaled treatment and patients may experience acute flare ups requiring courses of steroids and eventually hospitalization leading to a poor quality of life. New biological drugs have been introduced to treat severe asthma characterized by inflammation in the blood and in the lungs. Benralizumab is a well known biological option for severe asthmatic patients. Methods: We provide data on 22 patients followed up in our tertiary severe asthma centre in Tradate, Italy, affected by severe eosinophilic asthma treated with benralizumab for at least one year. Results: Our data confirmed a rapid effect of benralizumab on respiratory symptoms, exacerbations and quality of life. In addition, we documented a significant improvement in lung function along with a normalization of inflammation in the blood and in the lungs, assessed with a non-invasive tool: the induced sputum. Conclusions: Interestingly, our data highlight the importance of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Additional studies are needed to implement its role in the management of asthma also in terms of response to treatment towards a personalized approach. Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation. This is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients. We conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months. Twenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment ( < 0.0001) as well as an improvement in asthma control ( < 0.0001), health-related quality of life ( = 0.017) and lung function pre-BD FEV1 (L) ( = 0.02) and percentage ( = 0.004) and post-BD FEV1 (L) ( = 0.01) and percentage ( = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 ( < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = -0.79, = 0.04). Moreover, the improvement of FEF from baseline to 6 (rho = -0.53, = 0.03) and 12 (rho = -0.62, = 0.01) months negatively correlated with the duration of asthma disease.In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation. Our data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission. |
| Author | Visca, Dina Pini, Laura Spanevello, Antonio Pignatti, Patrizia Centis, Rosella Ardesi, Francesco Zappa, Martina Vanetti, Marco Grossi, Sarah Sotgiu, Giovanni Migliori, Giovanni Battista |
| Author_xml | – sequence: 1 givenname: Dina orcidid: 0000-0003-2298-1623 surname: Visca fullname: Visca, Dina email: dina.visca@icsmaugeri.it organization: Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, via Roncaccio 16, Tradate 21049, Italy – sequence: 2 givenname: Francesco surname: Ardesi fullname: Ardesi, Francesco organization: Department of Medicine and Surgery, University of Insubria, Varese, Italy – sequence: 3 givenname: Martina surname: Zappa fullname: Zappa, Martina organization: Department of Medicine and Surgery, University of Insubria, Varese, Italy – sequence: 4 givenname: Sarah surname: Grossi fullname: Grossi, Sarah organization: Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy – sequence: 5 givenname: Patrizia surname: Pignatti fullname: Pignatti, Patrizia organization: Allergy and Immunology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy – sequence: 6 givenname: Marco orcidid: 0009-0007-3782-5021 surname: Vanetti fullname: Vanetti, Marco organization: Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy – sequence: 7 givenname: Laura surname: Pini fullname: Pini, Laura organization: Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy – sequence: 8 givenname: Giovanni surname: Sotgiu fullname: Sotgiu, Giovanni organization: Department of Medical, Surgical and Experimental Sciences, Clinical Epidemiology and Medical Statistics Unit, University of Sassari, Sassari, Italy – sequence: 9 givenname: Rosella orcidid: 0000-0002-8551-3598 surname: Centis fullname: Centis, Rosella organization: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy – sequence: 10 givenname: Giovanni Battista surname: Migliori fullname: Migliori, Giovanni Battista organization: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy – sequence: 11 givenname: Antonio surname: Spanevello fullname: Spanevello, Antonio organization: Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39686520$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kltrFTEUhYNU7EV_gC8y4IsvU5PJbeKLSPFSKIhQn0OS2Tknh8ykJjOF-uvNOafWtqJPSVbW-tjZO8foYEoTIPSS4FNCpHxLJKdMCNExQjETPX-CjrZauxUP7u0P0XEpG4y5wrJ_hg6pEr3gHT5C3y7X0ID34OYm-cbClE0MP5fR2CZNTZh8NONo5rA7NAWuIUNjyrwezbvGNBlMbGPwVZtMvCmhPEdPvYkFXtyuJ-j7p4-XZ1_ai6-fz88-XLSOUzq3gx-kwEAt4eA7sEr2TnVKMMuUYoZbZ7HnAM5jNjAslSO-52AtFZ1VgOkJOt9zh2Q2-iqH0eQbnUzQOyHllTZ5Di6Ctp4IYoQHKh0brLRSKjUQo4Zu4E72lfV-z7pa7AiDg2mubXgAfXgzhbVepWtNiOCYY1YJb24JOf1YoMx6DMVBjGaCtBRNCROKSEF4tb5-ZN2kJdfubV2V1ikqtsBX90u6q-X36KqB7A0up1Iy-DsLwXr7PfRf36Nm5KOMC_NuuPVVIf43ebpPFrOCPwX_O_ALHiPKpg |
| CitedBy_id | crossref_primary_10_3390_jcm14082623 crossref_primary_10_1016_j_anai_2025_09_002 |
| Cites_doi | 10.1016/S2213-2600(17)30190-X 10.1016/S0954-6111(06)80166-6 10.1016/S0140-6736(16)31322-8 10.1016/j.jaip.2019.06.035 10.1159/000530392 10.1136/bmj.39335.541782.AD 10.1164/rccm.201908-1590ST 10.1186/s12931-023-02539-7 10.1016/j.rmed.2016.01.003 10.1183/09031936.00112306 10.1016/j.chest.2020.08.2083 10.1111/j.1440-1843.2006.00784.x 10.1164/rccm.200801-060ST 10.1016/j.jaci.2013.05.020 10.1111/cea.12762 10.1016/j.biopha.2020.110444 10.1016/S2213-2600(20)30414-8 10.1016/j.waojou.2018.12.001 10.1080/02770903.2024.2332351 10.3389/fphys.2019.01514 10.1016/j.jaip.2021.08.004 10.1016/S2213-2600(21)00352-0 10.15586/aei.v50i6.704 10.1159/000525846 10.1016/S2213-2600(18)30406-5 10.1016/j.waojou.2023.100805 10.1164/ajrccm.164.5.2011026 10.1016/j.rmed.2020.106202 10.1136/thorax-2022-219781 10.1186/s12931-022-01952-8 10.1183/23120541.00383-2023 10.1016/j.jaci.2014.04.005 10.1016/j.jaci.2003.09.008 10.3109/02770908509087113 10.1016/j.rmed.2014.10.007 10.1016/S0140-6736(16)31324-1 10.1183/13993003.00930-2019 10.1056/NEJMoa1703501 10.1155/2006/189127 10.1016/j.jaci.2019.12.006 10.1034/j.1399-3003.1999.14d29.x |
| ContentType | Journal Article |
| Copyright | The Author(s), 2024 The Author(s), 2024. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s), 2024 2024 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| Copyright_xml | – notice: The Author(s), 2024 – notice: The Author(s), 2024. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s), 2024 2024 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| DBID | AFRWT AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1177/17534666241304685 |
| DatabaseName | Sage Journals GOLD Open Access 2024 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1753-4666 |
| ExternalDocumentID | oai_doaj_org_article_bf161a6fe37c4db7b7799d1a9d2d5c78 PMC11650504 39686520 10_1177_17534666241304685 10.1177_17534666241304685 |
| Genre | Journal Article Observational Study |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GrantInformation_xml | – fundername: Ministry of Health, Italy. grantid: Partially funded by the Ricerca Corrente scheme – fundername: ; grantid: Partially funded by the Ricerca Corrente scheme |
| GroupedDBID | --- -TM 01A 0R~ 123 29Q 4.4 53G 54M 5VS 7X7 8FI 8FJ AABMB AABOD AADUE AAQDB AARDL AARIX AASGM ABAFQ ABAWP ABEIX ABFWQ ABJIS ABKRH ABQXT ABRHV ABUWG ABVFX ACARO ACDSZ ACDXX ACGFS ACOFE ACROE ACRPL ADBBV ADEBD ADNMO ADOGD ADYCS ADZZY AENEX AEQLS AERKM AEUHG AEWDL AEXNY AFCOW AFEET AFKRA AFKRG AFRWT AFUIA AFWMB AGNHF AGQPQ AHHFK AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ARTOV ASPBG AVWKF AZFZN B8M BCNDV BDDNI BENPR BKSCU BPHCQ BSEHC BVXVI BYIEH CAG CCPQU CDWPY CFDXU COF CS3 DC- DC. DOPDO EBS EJD EMOBN F5P FEDTE FYUFA GROUPED_DOAJ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HMCUK HVGLF HYE HZ~ J8X K.F N9A O9- OK1 P.B PHGZM PHGZT PIMPY PQQKQ ROL RPM S01 SAUOL SCDPB SCNPE SFC UKHRP ZONMY ZPPRI ZRKOI ZSSAH AAYXX ACHEB AFFHD CITATION CGR CUY CVF ECM EIF M4V NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c533t-dfd760e3b15ef2eb978c92964b4994a5bcb0f5eecf04d4079c1f85ebb362b9e03 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001379603700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1753-4666 1753-4658 |
| IngestDate | Mon Nov 10 04:33:17 EST 2025 Tue Nov 04 02:04:52 EST 2025 Fri Sep 05 09:28:27 EDT 2025 Tue Oct 07 06:58:39 EDT 2025 Sun Mar 30 02:11:08 EDT 2025 Tue Nov 18 21:26:42 EST 2025 Sat Nov 29 08:09:33 EST 2025 Tue Jun 17 22:26:47 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | airway inflammation disease control induced sputum severe asthma lung function benralizumab |
| Language | English |
| License | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c533t-dfd760e3b15ef2eb978c92964b4994a5bcb0f5eecf04d4079c1f85ebb362b9e03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-2298-1623 0009-0007-3782-5021 0000-0002-8551-3598 |
| OpenAccessLink | https://www.proquest.com/docview/3150529364?pq-origsite=%requestingapplication% |
| PMID | 39686520 |
| PQID | 3150529364 |
| PQPubID | 4450849 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bf161a6fe37c4db7b7799d1a9d2d5c78 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11650504 proquest_miscellaneous_3146917615 proquest_journals_3150529364 pubmed_primary_39686520 crossref_primary_10_1177_17534666241304685 crossref_citationtrail_10_1177_17534666241304685 sage_journals_10_1177_17534666241304685 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-01 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London, England |
| PublicationPlace_xml | – name: London, England – name: England – name: Thousand Oaks – name: Sage UK: London, England |
| PublicationTitle | Therapeutic advances in respiratory disease |
| PublicationTitleAlternate | Ther Adv Respir Dis |
| PublicationYear | 2024 |
| Publisher | SAGE Publications SAGE PUBLICATIONS, INC SAGE Publishing |
| Publisher_xml | – name: SAGE Publications – name: SAGE PUBLICATIONS, INC – name: SAGE Publishing |
| References | Graff, Bricmont, Moermans 2020; 175 Graham, Steenbruggen, Miller 2019; 200 Bleecker, FitzGerald, Chanez 2016; 388 Chiu, Hsiao, Su 2020; 8 ten Brinke, Zwinderman, Sterk 2001; 164 Tsubokawa, Koya, Murai 2023; 184 Chachi, Diver, Kaul 2019; 54 Menzella, Fontana, Galeone 2021; 16 Nolasco, Crimi, Pelaia 2021; 9 Belda, Parameswaran, Lemière 2006; 13 Schleich, Moermans, Seidel 2023; 9 Harrison, Chanez, Menzella 2021; 9 Balbi, Pignatti, Corradi 2007; 30 FitzGerald, Bleecker, Nair 2016; 388 Pelaia, Busceti, Crimi 2020; 129 von Elm, Altman, Egger 2007; 335 Pelaia, Paoletti, Puggioni 2019; 10 Ferguson, FitzGerald, Bleecker 2017; 5 Kavanagh, Hearn, Dhariwal 2021; 159 Canonica, Colombo, Bruno 2019; 12 Menzies-Gow, Gurnell, Heaney 2022; 10 Martinez-Moragon, Chiner, Suliana Mogrovejo 2024; 1 Pham, Damera, Newbold 2016; 111 Reddel, Taylor, Bateman 2009; 180 Simpson, Scott, Boyle 2006; 11 Walsh, Zaihra, Benedetti 2016; 46 Miralles-López, Andújar-Espinosa, Bravo-Gutiérrez 2022; 50 Laviolette, Gossage, Gauvreau 2013; 132 Padilla-Galo, Moya Carmona, Ausín 2023; 24 Schleich, Brusselle, Louis 2014; 108 Nair, Wenzel, Rabe 2017; 376 Wecker, Tizek, Ziehfreund 2023; 16 Juniper, O’Byrne, Guyatt 1999; 14 Nathan, Sorkness, Kosinski 2004; 113 Jones, Quirk, Baveystock 1991; 85 Newby, Agbetile, Hargadon 2014; 134 Menzella, Bargagli, Aliani 2022; 23 Gerday, Graff, Moermans 2023; 78 Menzies-Gow, Bafadhel, Busse 2020; 145 Busse, Bleecker, FitzGerald 2019; 7 Paggiaro, Chanez, Holz 2002; 37 Fanta 1985; 22 Sakai, Koya, Murai 2023; 184 bibr14-17534666241304685 bibr17-17534666241304685 bibr24-17534666241304685 bibr34-17534666241304685 bibr37-17534666241304685 bibr27-17534666241304685 bibr32-17534666241304685 bibr35-17534666241304685 bibr41-17534666241304685 bibr7-17534666241304685 bibr44-17534666241304685 bibr21-17534666241304685 bibr4-17534666241304685 bibr31-17534666241304685 bibr11-17534666241304685 bibr1-17534666241304685 bibr8-17534666241304685 bibr43-17534666241304685 bibr33-17534666241304685 bibr40-17534666241304685 bibr10-17534666241304685 bibr20-17534666241304685 bibr28-17534666241304685 bibr2-17534666241304685 bibr38-17534666241304685 bibr25-17534666241304685 bibr12-17534666241304685 bibr18-17534666241304685 bibr5-17534666241304685 bibr15-17534666241304685 Paggiaro PL (bibr30-17534666241304685) 2002; 37 bibr3-17534666241304685 bibr22-17534666241304685 bibr19-17534666241304685 bibr29-17534666241304685 bibr16-17534666241304685 bibr6-17534666241304685 bibr13-17534666241304685 bibr9-17534666241304685 bibr36-17534666241304685 bibr23-17534666241304685 bibr26-17534666241304685 bibr39-17534666241304685 Menzella F (bibr42-17534666241304685) 2021; 16 |
| References_xml | – volume: 14 start-page: 902 issue: 4 year: 1999 end-page: 907 article-title: Development and validation of a questionnaire to measure asthma control publication-title: Eur Respir J – volume: 54 start-page: 1900930 issue: 5 year: 2019 article-title: Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma publication-title: Eur Respir J – volume: 37 year: 2002 article-title: Sputum induction publication-title: Eur Respir J Suppl – volume: 16 start-page: 785 issue: 1 year: 2021 article-title: Real world effectiveness of benralizumab on respiratory function and asthma control publication-title: Multidiscip Respir Med – volume: 184 start-page: 243 issue: 3 year: 2023 end-page: 251 article-title: Effects of benralizumab on three-dimensional computed tomography analysis in severe eosinophilic asthma publication-title: Int Arch Allergy Immunol – volume: 200 issue: 8 year: 2019 article-title: Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society Technical Statement publication-title: Am J Respir Crit Care Med – volume: 113 start-page: 59 issue: 1 year: 2004 end-page: 65 article-title: Development of the asthma control test: a survey for assessing asthma control publication-title: J Allergy Clin Immunol – volume: 10 start-page: 1514 year: 2019 article-title: Interleukin-5 in the pathophysiology of severe asthma publication-title: Front Physiol – volume: 9 issue: 12 year: 2021 article-title: Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study publication-title: J Allergy Clin Immunol Pract – volume: 388 start-page: 2128 issue: 10056 year: 2016 end-page: 2141 article-title: Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet – volume: 145 start-page: 757 issue: 3 year: 2020 end-page: 765 article-title: An expert consensus framework for asthma remission as a treatment goal publication-title: J Allergy Clin Immunol – volume: 134 start-page: 287 issue: 2 year: 2014 end-page: 294 article-title: Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma publication-title: J Allergy Clin Immunol – volume: 30 start-page: 769 issue: 4 year: 2007 end-page: 781 article-title: Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults publication-title: Eur Respir J – volume: 129 start-page: 110444 year: 2020 article-title: Real-life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma publication-title: Biomed Pharmacother – volume: 23 start-page: 36 issue: 1 year: 2022 article-title: ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study publication-title: Respir Res – volume: 132 issue: 5 year: 2013 article-title: Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia publication-title: J Allergy Clin Immunol – volume: 164 start-page: 744 issue: 5 year: 2001 end-page: 748 article-title: Factors associated with persistent airflow limitation in severe asthma publication-title: Am J Respir Crit Care Med – volume: 9 start-page: 260 issue: 3 year: 2021 end-page: 274 article-title: Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial publication-title: Lancet Respir Med – volume: 184 start-page: 783 issue: 8 year: 2023 end-page: 791 article-title: Effect of benralizumab on mucus plugs in severe eosinophilic asthma publication-title: Int Arch Allergy Immunol – volume: 335 start-page: 806 year: 2007 end-page: 808 article-title: Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies publication-title: BMJ – volume: 159 start-page: 496 issue: 2 year: 2021 end-page: 506 article-title: Real-world effectiveness of benralizumab in severe eosinophilic asthma publication-title: Chest – volume: 78 start-page: 1138 issue: 11 year: 2023 end-page: 1141 article-title: Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline publication-title: Thorax – volume: 10 start-page: 47 issue: 1 year: 2022 end-page: 58 article-title: Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study publication-title: Lancet Respir Med – volume: 13 start-page: 129 issue: 3 year: 2006 end-page: 133 article-title: Predictors of loss of asthma control induced by corticosteroid withdrawal publication-title: Can Respir J – volume: 180 start-page: 59 issue: 1 year: 2009 end-page: 99 article-title: An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice publication-title: Am J Respir Crit Care Med – volume: 24 start-page: 235 issue: 1 year: 2023 article-title: Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study publication-title: Respir Res – volume: 16 start-page: 100805 issue: 8 year: 2023 article-title: Impact of asthma in Europe: a comparison of web search data in 21 European countries publication-title: World Allergy Organ J – volume: 22 start-page: 295 issue: 6 year: 1985 end-page: 301 article-title: Clinical aspects of mucus and mucous plugging in asthma publication-title: J Asthma – volume: 1 start-page: 1190 issue: 10 year: 2024 end-page: 1204 article-title: Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma publication-title: J Asthma – volume: 46 start-page: 1291 issue: 10 year: 2016 end-page: 1302 article-title: Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils publication-title: Clin Exp Allergy – volume: 388 start-page: 2115 issue: 10056 year: 2016 end-page: 2127 article-title: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β publication-title: Lancet – volume: 5 start-page: 568 issue: 7 year: 2017 end-page: 576 article-title: Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Respir Med – volume: 12 start-page: 100007 issue: 1 year: 2019 article-title: Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry publication-title: World Allergy Organ J – volume: 376 start-page: 2448 issue: 25 year: 2017 end-page: 2458 article-title: Oral glucocorticoid-sparing effect of benralizumab in severe asthma publication-title: N Engl J Med – volume: 11 start-page: 54 issue: 1 year: 2006 end-page: 61 article-title: Inflammatory subtypes in asthma: assessment and identification using induced sputum publication-title: Respirology – volume: 9 start-page: 00383 issue: 6 year: 2023 end-page: 2023 article-title: Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia publication-title: ERJ Open Res – volume: 7 start-page: 46 issue: 1 year: 2019 end-page: 59 article-title: Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial publication-title: Lancet Respir Med – volume: 111 start-page: 21 year: 2016 end-page: 29 article-title: Reductions in eosinophil biomarkers by benralizumab in patients with asthma publication-title: Respir Med – volume: 175 start-page: 106202 year: 2020 article-title: Clinical and biological factors associated with irreversible airway obstruction in adult asthma publication-title: Respir Med – volume: 50 start-page: 163 issue: 6 year: 2022 end-page: 168 article-title: Analysis of response of severe eosinophilic asthmatic patients to benralizumab publication-title: Allergol Immunopathol (Madr) – volume: 8 issue: 1 year: 2020 article-title: Small Airway dysfunction by impulse oscillometry in symptomatic patients with preserved pulmonary function publication-title: J Allergy Clin Immunol Pract – volume: 108 start-page: 1723 issue: 12 year: 2014 end-page: 1732 article-title: Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR) publication-title: Respir Med – volume: 85 start-page: 25 year: 1991 end-page: 31 article-title: The St George’s Respiratory Questionnaire publication-title: Respir Med – ident: bibr14-17534666241304685 doi: 10.1016/S2213-2600(17)30190-X – ident: bibr25-17534666241304685 doi: 10.1016/S0954-6111(06)80166-6 – ident: bibr13-17534666241304685 doi: 10.1016/S0140-6736(16)31322-8 – ident: bibr44-17534666241304685 doi: 10.1016/j.jaip.2019.06.035 – ident: bibr19-17534666241304685 doi: 10.1159/000530392 – ident: bibr22-17534666241304685 doi: 10.1136/bmj.39335.541782.AD – ident: bibr29-17534666241304685 doi: 10.1164/rccm.201908-1590ST – ident: bibr35-17534666241304685 doi: 10.1186/s12931-023-02539-7 – ident: bibr11-17534666241304685 doi: 10.1016/j.rmed.2016.01.003 – ident: bibr32-17534666241304685 doi: 10.1183/09031936.00112306 – ident: bibr27-17534666241304685 doi: 10.1016/j.chest.2020.08.2083 – ident: bibr31-17534666241304685 doi: 10.1111/j.1440-1843.2006.00784.x – ident: bibr26-17534666241304685 doi: 10.1164/rccm.200801-060ST – ident: bibr38-17534666241304685 doi: 10.1016/j.jaci.2013.05.020 – ident: bibr9-17534666241304685 doi: 10.1111/cea.12762 – volume: 16 start-page: 785 issue: 1 year: 2021 ident: bibr42-17534666241304685 publication-title: Multidiscip Respir Med – ident: bibr5-17534666241304685 doi: 10.1016/j.biopha.2020.110444 – ident: bibr1-17534666241304685 – volume: 37 year: 2002 ident: bibr30-17534666241304685 publication-title: Eur Respir J Suppl – ident: bibr33-17534666241304685 doi: 10.1016/S2213-2600(20)30414-8 – ident: bibr3-17534666241304685 doi: 10.1016/j.waojou.2018.12.001 – ident: bibr20-17534666241304685 doi: 10.1080/02770903.2024.2332351 – ident: bibr6-17534666241304685 doi: 10.3389/fphys.2019.01514 – ident: bibr43-17534666241304685 doi: 10.1016/j.jaip.2021.08.004 – ident: bibr17-17534666241304685 doi: 10.1016/S2213-2600(21)00352-0 – ident: bibr36-17534666241304685 doi: 10.15586/aei.v50i6.704 – ident: bibr39-17534666241304685 doi: 10.1159/000525846 – ident: bibr16-17534666241304685 doi: 10.1016/S2213-2600(18)30406-5 – ident: bibr2-17534666241304685 doi: 10.1016/j.waojou.2023.100805 – ident: bibr10-17534666241304685 doi: 10.1164/ajrccm.164.5.2011026 – ident: bibr40-17534666241304685 doi: 10.1016/j.rmed.2020.106202 – ident: bibr21-17534666241304685 doi: 10.1136/thorax-2022-219781 – ident: bibr18-17534666241304685 doi: 10.1186/s12931-022-01952-8 – ident: bibr34-17534666241304685 doi: 10.1183/23120541.00383-2023 – ident: bibr8-17534666241304685 doi: 10.1016/j.jaci.2014.04.005 – ident: bibr24-17534666241304685 doi: 10.1016/j.jaci.2003.09.008 – ident: bibr41-17534666241304685 doi: 10.3109/02770908509087113 – ident: bibr4-17534666241304685 doi: 10.1016/j.rmed.2014.10.007 – ident: bibr12-17534666241304685 doi: 10.1016/S0140-6736(16)31324-1 – ident: bibr37-17534666241304685 doi: 10.1183/13993003.00930-2019 – ident: bibr15-17534666241304685 doi: 10.1056/NEJMoa1703501 – ident: bibr7-17534666241304685 doi: 10.1155/2006/189127 – ident: bibr28-17534666241304685 doi: 10.1016/j.jaci.2019.12.006 – ident: bibr23-17534666241304685 doi: 10.1034/j.1399-3003.1999.14d29.x |
| SSID | ssj0059078 |
| Score | 2.3088028 |
| Snippet | Background:
Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and... Plain language summary Analysis of the effect of a biological therapy on severe asthma Background: Asthma is estimated to affect almost 5%-8% of the European... Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its... Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and... Analysis of the effect of a biological therapy on severe asthma Background: Asthma is estimated to affect almost 5%-8% of the European adult population, and... |
| SourceID | doaj pubmedcentral proquest pubmed crossref sage |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 17534666241304685 |
| SubjectTerms | Adult Aged Anti-Asthmatic Agents - pharmacology Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Asthma Asthma - diagnosis Asthma - drug therapy Asthma - physiopathology Eosinophils - drug effects Female Forced Expiratory Volume Humans Inflammation Italy Lung - drug effects Lung - immunology Lung - physiopathology Male Middle Aged Monoclonal antibodies Original Research Pulmonary Eosinophilia - diagnosis Pulmonary Eosinophilia - drug therapy Pulmonary Eosinophilia - immunology Pulmonary Eosinophilia - physiopathology Quality of Life Retrospective Studies Severity of Illness Index Sputum - cytology Sputum - immunology Time Factors Treatment Outcome |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5CKKGX0jZ9uEmLAoVCwVReybKVW1IaekhCCi3kZvQYkYWNt-yjh_76jiztZpf0cenRkozFzEjzjUf6BuBt1VCPRV6aVvtSiqBK2gMdLTzSPzpPHn-4KHzeXF6219f6aqPUVzwTluiBk-A-2ECYxKiAonHS28Y2jda-MtqPfO2a4ZovoZ5VMJX24JpCvjbnMCO9UqSjlATUhySSVLFw8oYXGsj6f4cw7x-U3DjtNTigs8fwKCNHdpJm_AR2sH8Kexc5N74PX0jjLB3PYNPALBkGYeyfy1tj2bRnZEmk_HRRkR4YeUScITPzxc2tOWaGEXqclJNxoLZMVPIMvp19-vrxc5kLJpSOUNui9ME3iqOwVY1hhJYiRKdjXtVSXCNNbZ3loUZ0gUtPkZx2VWhrtJa8mNXIxXPY7ac9vgQmndDovbIyRpBB6dZ44SrfWuODq1QBfCXAzmU28VjUYtJVmUD8nswLeL9-5Xui0vjb4NOolfXAyII9NJBtdNk2un_ZRgGHK512eWnOO1HF2n1aKFnA0bqbFlXMlJgep8s4RiqKYwntFfAimcB6JkKrVtUjXkC7ZRxbU93u6cc3A3F3pDriNacPv4t2dDenP4rh1f8QwwE8HBEUSz-ODmF3MVvia3jgfizG89mbYeH8AuyNGfY priority: 102 providerName: Directory of Open Access Journals |
| Title | The effect of benralizumab on inflammation in severe asthma: a real-life analysis |
| URI | https://journals.sagepub.com/doi/full/10.1177/17534666241304685 https://www.ncbi.nlm.nih.gov/pubmed/39686520 https://www.proquest.com/docview/3150529364 https://www.proquest.com/docview/3146917615 https://pubmed.ncbi.nlm.nih.gov/PMC11650504 https://doaj.org/article/bf161a6fe37c4db7b7799d1a9d2d5c78 |
| Volume | 18 |
| WOSCitedRecordID | wos001379603700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1753-4666 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059078 issn: 1753-4666 databaseCode: DOA dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1753-4666 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059078 issn: 1753-4666 databaseCode: 7X7 dateStart: 20071001 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1753-4666 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059078 issn: 1753-4666 databaseCode: BENPR dateStart: 20071001 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 1753-4666 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059078 issn: 1753-4666 databaseCode: PIMPY dateStart: 20071001 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-xDiFexjcLjMpISEhIEUnj2DEviKFNILGqIJDKU-RPVqlLtn7sYX_9zo7brRrshZdKsV3V6d35fuezfwfwJufYo2yWykqYlBaOpbgGajQ8lL_VBj1-uCj8jQ-H1XgsRnHDbR6PVa7WxLBQm1b7PfL3Re5LromC0Y-nZ6mvGuWzq7GExhZse6Yy2oPt_YPh6MdqLS4x9AuX4RCUpxSdbcxresol30YRvIfEEmW-mPI1zxQI_P-GOm8enrx2Aiw4pcMH__s6D2EnwlHyqdOfR3DHNo_h3lFMuD-B76hGpDvzQVpHFGobAveL5YlUpG0IqidqVHf7ER8Iulk7s0TOF8cn8gORBCHpNJ1OHLZF9pOn8Ovw4OfnL2mswpBqhIKL1DjDWWYLlZfWDazCsFMLn6xVGCxRWSqtMldaq11GDYaHQueuKq1S6BqVsFnxDHpN29hdIFQXwhrDFPVhqWOikqbQuamUNE7nLIFsJYFaR4pyXyljWueRlfyG0BJ4t_7KacfPcdvgfS_W9UBPrR0a2tmfOlpqrRyCYMmcLbimRnHFuRAml8IMTKl5lcDeSqJ1tPd5fSXOBF6vu9FSffpFNrZd-jGUYXCMEDKB550OrWdSCFaxcpAlUG1o18ZUN3uayXFgA_f8SVmZ4Q-_9Yp4Nad__g0vbn-Dl3B_gMit22fag95itrSv4K4-X0zmsz5s8TEPn1U_Wls_bGTg0-jr0ej3JZENLrM |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwEB6VLQJeuI9AASOBkJAicjhOjIQQV9VVd1dFKlL7FHzSlbZJ2QMEP4rfyDhxtl0V-tYHHtd2sk48M_6-zHgG4GmcY480USgKrkOaWhaiDVSoeLj-Rmnc8ZuDwoN8NCr29vjOGvzuzsK4sMrOJjaGWtfKfSN_mcau5BpPGX1z9C10VaOcd7UrodGKxbb5-QMp2-x1_wOu77Mk2fy4-34r9FUFQoXQZh5qq3MWmVTGmbGJkUijFHfOR4ngn4pMKhnZzBhlI6qR7nAV2yIzUqKpl9xEKd73AqxTFPaiB-s7_eHOfmf7M6SazeE7JAEhxc3d-1FdiifXRpEsNI4sylzx5hM7YVMw4G8o93Sw5omIs2YT3Lz2v72-63DVw23yttWPG7BmqptwaegDCm7BJ1QT0sa0kNoSidqExOTX4lBIUlcE1Q81pj3diT8IwggzNUTM5geH4hURBCH3JJyMLbb57C634fO5PNAd6FV1Ze4BoSrlRmsmqaPdlvFC6FTFupBCWxWzAKJuxUvlU7C7SiCTMvZZ108JSQAvlpcctflHzhr8zonRcqBLHd401NOvpbdEpbQI8gWzJs0V1TKXec65jgXXic5UXgSw0UlQ6e3ZrDwWnwCeLLvREjn3kqhMvXBjKEPyjxA5gLutzC5nknJWsCyJAihWpHllqqs91figyXbu8kNFWYR__NwJ_vGc_vka7p_9BI_h8tbucFAO-qPtB3AlQZTaflPbgN58ujAP4aL6Ph_Ppo-8dhP4ct4a8QcsT4l8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+benralizumab+on+inflammation+in+severe+asthma%3A+a+real-life+analysis&rft.jtitle=Therapeutic+advances+in+respiratory+disease&rft.au=Visca+Dina&rft.au=Ardesi+Francesco&rft.au=Zappa+Martina&rft.au=Grossi%2C+Sarah&rft.date=2024-01-01&rft.pub=SAGE+PUBLICATIONS%2C+INC&rft.issn=1753-4658&rft.eissn=1753-4666&rft.volume=18&rft_id=info:doi/10.1177%2F17534666241304685 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1753-4666&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1753-4666&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1753-4666&client=summon |